![]() |
|
|
Vol. 287, Issue 2, 441-447, November 1998
Department of Psychiatry (R.Y., T.T., K.A.) and Department of Pharmacology (N.Y., Y.U., Y.T., S.U., F.I.), University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan
| |
Abstract |
|---|
|
|
|---|
Treatment of cultured bovine adrenal medullary cells with carbamazepine (CBZ) for 5 days caused an increase in catecholamine secretion induced by veratridine, an activator of voltage-dependent Na+ channels. However, no increase was stimulated by carbachol, an agonist of nicotinic receptors, or by 56 mM K+, a depolarizing agent that activates voltage-dependent Ca++ channels. CBZ (30 µg/ml) treatment enhanced veratridine-induced catecholamine secretion in a time-dependent manner (increases of 25%, 65% and 70% for 3, 5 and 7 days of treatment, respectively). CBZ treatment (5 days) increased veratridine-induced catecholamine secretion in a concentration-dependent manner (increases of 27%, 36%, 45% and 55% at 10, 15, 20 and 30 µg/ml of CBZ, respectively). CBZ treatment also increased 22Na+ influx and 45Ca++ influx stimulated by veratridine. The stimulatory effect of CBZ treatment on catecholamine secretion was blocked by either actinomycin D or cycloheximide, an inhibitor of protein synthesis. Additive responses of catecholamine secretion and 22Na+ influx induced by veratridine were associated with combined exposure of the cells to CBZ and dibutyryl cyclic AMP. CBZ treatment (30 µg/ml, 5 days) significantly increased the specific binding of [3H]saxitoxin to cell membranes. A Scatchard analysis of [3H]saxitoxin binding revealed that CBZ increased the Bmax value without any change in the dissociation constant. These findings suggest that CBZ up-regulates the density and activity of voltage-dependent Na+ channels.
| |
Introduction |
|---|
|
|
|---|
CBZ,
an anticonvulsant with a structure similar to that of the tricyclic
antidepressant imipramine, is well known to be effective in the
treatment of seizure disorder and has been shown to have subsidary uses
in trigeminal neuralgia and paroxysmal pain (Parnas et al.,
1980
). A recent report by Post et al. (1990)
provided substantial evidence that CBZ induces acute antimanic effects. There
are also several reports that CBZ is effective in acute depression
(Neumann et al., 1984
; Post et al., 1986
; Small,
1990
), in treatment of some schizophrenic patients (Hakola and
Laulumaa, 1982
) and in benzodiazepine and alcohol withdrawal (Denicoff
et al., 1994
). In regard to its mechanism, CBZ has been
proposed to exert its effects by acting on various ion channels and
receptors. For example, CBZ is known to inhibit sodium channels (Willow
et al., 1984
; McLean and Macdonald, 1986
); to bind adenosine
A1 (Clark and Post, 1990
; Van Calleer et al.,
1991
), peripheral-type benzodiazepine (Weiss et al., 1985
;
1986
) and GABAB receptors (Terrence et al., 1983
; Motohashi et al., 1989
); to enhance
4-aminopyridine-sensitive potassium currents (Zona et al.,
1990
; Olpe et al., 1991
) and to inhibit NMDA-evoked
Ca++ influx (Lampe and Bigalke, 1990
; Hough et
al., 1996
). The pharmacological mechanism by which CBZ exerts its
clinical effects, however, is not well established.
Adrenal medullary cells that are derived from embryonic neural
crest share many physiological and pharmacological properties with
sympathetic postganglionic neurons. Bovine adrenal medullary cells
contain at least three kinds of ion channels that are involved in
catecholamine secretion (Wada et al., 1985
). These are
voltage-dependent Na+ channels (Amy and Kirshner, 1982
),
nicotinic ACh receptor-associated ion channels (Amy and Kirshner, 1982
)
and voltage-dependent Ca++ channels (Kilpatrick et
al., 1982
). Ion channel-mediated catecholamine secretion has been
extensively studied in the adrenal medullary cells, and the mechanism
of catecholamine secretion from these cells is thought to be similar to
that of neurotransmitter released from noradrenergic nerve terminals in
the brain (Pocock and Richards, 1988
). Accordingly, these cells are a
good model for detailed analysis of the action of psychotropic drugs
such as tricyclic and tetracyclic antidepressants (Arita et
al., 1987
) and lithium chloride (Terao et al., 1992
) on
the central noradrenergic neurons.
Recently, we reported that short-term treatment (5 min) with CBZ
inhibits catecholamine secretion by interfering with nicotinic ACh
receptor-associated ion channels, voltage-dependent Na+
channels and N-type voltage-dependent Ca++ channels in
adrenal medullary cells (Yoshimura et al., 1995
). However,
there may be significant differences between the action of CBZ on ion
channels in acute and chronic treatments, and chronic CBZ treatment is
necessary to achieve clinical efficacy for neuropsychiatric disorders.
In the present study, we investigated the effect of long-term treatment
(5 days) with CBZ on catecholamine secretion in bovine adrenal
medullary cells.
| |
Materials and Methods |
|---|
|
|
|---|
Materials. KRP buffer containing (mM) NaCl 154, KCl 5.6, MgSO4 1.1, CaCl2 2.2, NaH2PO4 0.85, Na2HPO4 2.15 and glucose 10 was oxygenated by bubbling with 100% O2 for at least 30 min and adjusted to pH 7.4. Drugs and chemicals used in this study were: Eagle's MEM (Nissui Seiyaku, Tokyo), CBZ, carbachol, veratridine, cycloheximide, actinomycin D and dbc AMP (Sigma Chemical Co., St Louis, MO), H89 (Seikagaku, Tokyo), collagenase (Nitta Zerachin, Osaka, Japan), TTX (Sankyo, Tokyo), [22Na]Cl (6-17 Ci/mmol) and [3H]STX (20-40 Ci/mmol) (New England Nuclear, Boston, MA) and [45Ca]Cl2 (0.5-2 Ci/mmol) (Amersham International, Amersham, UK).
Isolation of bovine adrenal medullary cells and their primary
culture.
Fresh bovine adrenal glands were used throughout all
experiments. Isolated adrenal medullary cells were obtained by
collagenase digestion of slices of adrenal medulla, as reported
previously by Yanagihara et al. (1979)
. Cells were plated at
a density of 4 × 106 cells/dish (Falcon 35 mm) and
maintained in a monolayer culture in Eagle's MEM containing 10% calf
serum, 60 µg/ml aminobenzylpenicillin, 100 µg/ml streptomycin, 0.3 µg/ml amphotericin B and 3.0 µM cytosine arabinoside at 37°C
under 5% CO2/95% air (Yanagihara et al., 1994
) in a culture chamber. After 2 days of culturing, the cells were used
for experiments. For the treatment of cells with CBZ, the culture
medium was replaced with fresh CBZ medium once in 3 days. The CBZ
solution was prepared by dissolving CBZ in DMSO, followed by dilution
into Eagle's MEM. To avoid a possible influence of DMSO on cells, all
culture media, including control, were adjusted to a final
concentration of 0.1% DMSO, a level that has no effect on the ion
channel-mediated secretion of catecholamines (data not shown).
Secretion of catecholamines.
The secretion of catecholamines
was measured as described previously (Yanagihara et al.,
1979
). After 5 days of CBZ treatment, the cells were washed three times
with ice-cold KRP buffer and then reacted with a KRP buffer containing
various secretagogues in the absence of CBZ at 37°C for 5 min. The
reaction was terminated by aspiration and transference of the
incubation medium into a tube containing a perchloric acid solution
(final concentration, 0.4 M). Catecholamines (norepinephrine and
epinephrine) secreted into the medium were adsorbed onto aluminium
hydroxide and measured by the etylenediamine condensation method
(Weil-Malherbe and Bone, 1952
) using a fluorescence spectrophotometer
(Hitachi model 650-10S, Tokyo, Japan) with an excitation wavelength of
420 nm and an emission wavelength of 540 nm. At these wavelengths,
norepinephrine and epinephrine show the same fluorescence intensity
with minimum assay range of 20 ng. The recoveries of epinephrine and
norepinephrine by these procedures were 94% and 91%, respectively.
Catecholamines secreted into the medium were expressed as a percentage
of total catecholamines (norepinephrine plus epinephrine) in the cells. Total catecholamines were quantified by detaching cells from the dish,
transferring them into the tube containing perchloric acid (final
concentration, 0.4 M) and centrifuging them. Catecholamines in the
supernatant were assayed as described above.
Influx of 22Na+ and
45Ca++.
The influx of
22Na+ and 45Ca++ was
measured as described by Wada et al. (1985)
. Cells treated
with CBZ for 5 days were washed three times with ice-cold KRP buffer
and incubated with 1.5 µCi of 22NaCl or
45CaCl2 at 37°C for 5 min in 1 ml of KRP
buffer in the presence of veratridine (100 µM). Then the cells were
rapidly washed four times with 1 ml of ice-cold KRP buffer and
solubilized with 1 ml of 10% Triton X-100. 22Na in the
cells was counted by a gamma counter (Aloka ARC-2005), and
45Ca++ in the cells was counted by a liquid
scintillation counter (Beckman LS-7000). The influx of
22Na+ and 45Ca++ was
calculated from the initial specific radioactivity of these ions in the
incubation medium (KRP buffer).
[3H]STX binding. After treatment with CBZ (30 µg/ml) for 5 days, the cells were washed with ice-cold KRP buffer and incubated with 1 to 20 nM [3H]STX in 1 ml of KRP buffer at 4°C for 15 min in the absence (total binding) or presence (nonspecific binding) of 1 µM TTX. Cells were immediately washed twice with ice-cold KRP buffer, solubilized in 10% Triton X-100 and counted for radioactivity. Specific binding was calculated as the total binding minus the nonspecific binding.
Statistical analysis. All experiments were performed in duplicate or triplicate, and each experiment was repeated at least three times. Data obtained were given as the mean ± S.D. Statistical evaluation of unpaired observations was performed using Student's t test. When more than two means were compared, ANOVA was used. If a significant F value was found, Dunnett's or Scheffé's test for multiple comparisons was carried out to identify differences among groups. The former was used when the sample numbers were equal, the latter when the numbers were unequal.
| |
Results |
|---|
|
|
|---|
Effects of 5 days of CBZ treatment on catecholamine secretion induced by carbachol, veratridine and high K+. Carbachol (300 µM), an activator of nicotinic ACh receptor-associated ion channels, induced the secretion of catecholamines; the secreted fraction was 8% of the total catecholamines. Veratridine (100 µM), an activator of voltage-dependent Na+ channels, and 56 mM K+, a depolarizing agent, increased the catecholamine secretion to 9% and 8.5% of total catecholamines, respectively. Treatment with CBZ (30 µg/ml) for 5 days significantly increased the catecholamine secretion induced by veratridine (a 67% increase as compared with veratridine alone) (fig. 1). However, CBZ (30 µg/ml) did not increase the secretion of catecholamines induced by carbachol or high K+.
|
Effects of various concentrations of CBZ on catecholamine secretion induced by veratridine. Treatment with CBZ at concentrations of 10 to 30 µg/ml for 5 days significantly increased, in a concentration-dependent manner, the secretion of catecholamines induced by veratridine (fig. 2). The secretion was increased by 27%, 36%, 45% and 55% above the control (CBZ, 0 µg/ml) for 10, 15, 20 and 30 µg/ml of CBZ, respectively.
|
Change in veratridine-induced secretion of catecholamines after treatment with CBZ. CBZ (30 µg/ml) increased the secretion of catecholamines induced by veratridine in a time-dependent manner (3-7 days) (fig. 3). A significant increase in the catecholamine secretion was observed after treatment for 3 days (a 25% increase above the control at day 0), and the maximal level of catecholamine secretion was reached after 5 (65% increase over the control) to 7 days (70% increase over the control).
|
Effects of CBZ on 45Ca++ influx and 22Na+ influx induced by veratridine. Veratridine (100 µM) caused a 45Ca++ influx and a 22Na+ influx corresponding to 4.8 nmol/4 × 106 cells and 118 nmol/4 × 106 cells, respectively. Five days of treatment with CBZ (10 and 20 µg/ml) dose-dependently increased the influx of 45Ca++ and 22Na+ induced by veratridine (fig. 4A and B). The 45Ca++ influx was increased by 30% and 66% above the control (CBZ, 0 µg/ml) by 10 µg/ml and 20 µg/ml of CBZ, respectively (fig. 4A). The 22Na+ influx was increased by 37% and 61% above the control by 10 µg/ml and 20 µg/ml of CBZ, respectively (fig. 4B).
|
Effects of actinomycin D and cycloheximide on veratridine-induced catecholamine secretion in CBZ-treated cells. Treatment with CBZ (20 µg/ml) for 5 days increased the veratridine-induced catecholamine secretion by 60% of the control value. Actinomycin D (1 µg/ml), a drug used to inhibit the activity of DNA-dependent RNA polymerase, did not influence the catecholamine secretion but halted the increase of the catecholamine secretion caused by CBZ (fig. 5A). In addition, cycloheximide (1 µg/ml), an inhibitor of ribosomal synthesis of proteins, also reduced CBZ-increased catecholamine secretion to almost the same levels as in control cells or cells treated with cycloheximide alone (fig. 5B).
|
Effects of dbc AMP, H89 and CBZ on catecholamine secretion and
22Na+ influx induced by veratridine.
A
previous report (Yuhi et al., 1996
) describes how a
derivative of cAMP (an activator of cAMP-dependent protein kinase)
increases the number of functional voltage-dependent Na+
channels in cultured bovine adrenal medullary cells. In the present study, the authors found that dbc AMP (1 mM) also increased
veratridine-induced catecholamine secretion and
22Na+ influx. Simultaneous treatment with dbc
AMP (1 mM) and CBZ (30 µg/ml) caused an additive increase in
catecholamine secretion and 22Na+ influx
stimulated by veratridine (fig. 6).
Furthermore, H89 (an inhibitor of cAMP-dependent protein kinase) (10 µM) failed to influence either basal or CBZ-increased catecholamine
secretion or 22Na+ influx induced by
veratridine (fig. 6).
|
Effects of treatment with CBZ on [3H]STX binding. When cells were incubated with various concentrations (1-20 nM) of [3H]STX, the specific binding of [3H]STX was saturable (fig. 7A). Treatment with CBZ (20 µg/ml) for 5 days increased the specific binding of [3H]STX. A Scatchard plot analysis revealed that CBZ increased Bmax values from 18 ± 2 to 28 ± 2 fmol/4 × 106 cells without altering Kd values (control, 5.1 ± 1.1 nM; CBZ, 5.0 ± 1.0 nM) (fig. 7B).
|
| |
Discussion |
|---|
|
|
|---|
Long-term treatment with CBZ specifically influences
voltage-dependent Na+ channel-mediated secretion of
catecholamines.
In the present study, treatment of adrenal
medullary cells with CBZ enhanced catecholamine secretion induced by
veratridine in a concentration-dependent manner (10-30 µg/ml) (fig.
2). The concentrations of CBZ used (10-30 µg/ml) were slightly
higher than those (6-12 µg/ml) usually recommended for treating
neuropsychiatric disorders (McNamara, 1995
). CBZ (10-20 µg/ml, 5 days) also increased veratridine-induced 22Na+
influx and 45Ca++ influx in a manner similar to
that for catecholamine secretion (fig. 4). As shown in our previous
study (Wada et al., 1985
), the influx of Na+
via voltage-dependent Na+ channels causes a
depolarization of cell membranes, which in turn stimulates the influx
of Ca++ via voltage-dependent Ca++
channels and triggers the secretion of catecholamines. Therefore, it is
likely that CBZ treatment enhances 22Na+ influx
mediated through voltage-dependent Na+ channels, with
resultant increases of 45Ca++ influx and
catecholamine secretion. Our previous study showed that short-term
treatment (5 min) with CBZ inhibits both nicotinic ACh
receptor-associated ion channels and voltage-dependent Ca++
channels, as well as voltage-dependent Na+ channels, in
cultured adrenal medullary cells (Yoshimura et al., 1995
).
CBZ (30 µg/ml, 5 days), however, had little effect on catecholamine secretion stimulated by carbachol, an activator of nicotinic
ACh-associated ion channels, or on 56 mM K+, a depolarizing
agent that activates voltage-dependent Ca++ channels (fig.
1). These results indicate that long-term treatment with CBZ enhances
catecholamine secretion specifically by acting on voltage-dependent
Na+ channels.
Up-regulation of voltage-dependent Na+ channels by CBZ
treatment.
Treatment of adrenal medullary cells with CBZ for 5 days increased the specific binding of [3H]STX to cell
membranes (fig. 7A). The increase in specific binding of
[3H]STX was due to the increased number of binding sites,
but not to the change in the affinity toward [3H]STX
(fig. 7B). These findings suggest that CBZ treatment mediates the
up-regulation of Na+ channel proteins without altering
their pharmacological features. The precise mechanism of CBZ-induced
up-regulation of Na+ channels remains to be determined.
Both actinomycin D, which inhibits the activity of DNA-dependent RNA
polymerase, and cycloheximide, which inhibits ribosomal synthesis of
proteins, halted the stimulatory effect of CBZ on veratridine-induced
secretion (fig. 5), which suggests that CBZ treatment induces the
up-regulation of Na+ channels via a de
novo synthesis of its channel proteins in the cells. A previous
report by Yuhi et al. (1996)
showed that treatment of
cultured adrenal medullary cells with dbc AMP up-regulated the
functional voltage-dependent Na+ channels. In the present
study, the effects of dbc AMP and CBZ on veratridine-induced
catecholamine secretion, as well as on 22Na+
influx, were almost additive; furthermore, H89 (an inhibitor of
cAMP-dependent protein kinase) failed to abolish the stimulatory effect
of CBZ treatment (fig. 6). These results suggest that CBZ up-regulates
voltage-dependent Na+ channels by a mechanism that is
independent of cAMP.
-subunit. It
would therefore appear that further studies are needed to examine the
effect of CBZ exposure on levels of Na+ channel mRNA in
cultured adrenal medullary cells.
Antidepressive and anticonvulsive effects of CBZ.
In the
present study, we found that the increase in veratridine-induced
secretion of catecholamines was significant after CBZ treatment for 3 days and that it reached the maximal level after 5 to 7 days (fig. 3).
This may be related to the antidepressive effects of CBZ, which occur
at about 1 or 2 weeks after CBZ administration (Post et al.,
1994
). The original catecholamine hypothesis for the affective
disorders postulated that depression is characterized by a deficiency
of functional norepinephrine and that the brain norepinephrine levels
are recovered by treatment with antidepressants (Bunney and Davis,
1965
). Although current available evidence does not suggest uniform
increases or decreases in norepinephrine or its metabolites in plasma
and cerebrospiral fluid of depressed patients, results of studies to
date are consistent with some forms of bipolar depression being
associated with decreased norepinephrine release and metabolism and
some forms of unipolar depression being associated with increased
norepinephrine release and metabolism (Schildkraut et al.,
1978
; Siever and Uhde, 1984
). Therefore, the present findings suggest
the possibility that long administration of CBZ induces a change in
voltage-dependent Na+ channels and hence modulates
norepinephrine release in brain noradrenergic neurons of depressive patients.
| |
Footnotes |
|---|
Accepted for publication April 30, 1998.
Received for publication September 30, 1997.
Send reprint requests to: Dr. Nobuyuki Yanagihara, Department of Pharmacology, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
| |
Abbreviations |
|---|
CBZ, carbamazepine;
dbc AMP, dibutyryl cyclic
AMP;
H89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide;
KRP, Krebs-Ringer phosphate;
STX, saxitoxin;
TTX, tetrodotoxin;
Kd, dissociation constant;
GABA,
-aminobutyric acid;
NMDA, N-methyl-D-aspartate;
Eagle's
MEM, Eagle's minimum essential medium;
DMSO, dimethyl sulfoxide.
| |
References |
|---|
|
|
|---|
2-adrenergic agonist clonidine.
Biol Psychiatry
19:
131-156[Medline].
-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine.
Mol Pharmacol
22:
627-635[Abstract].This article has been cited by other articles:
![]() |
K. Kajiwara, T. Yanagita, Y. Nakashima, A. Wada, F. Izumi, and N. Yanagihara Differential Effects of Short and Prolonged Exposure to Carvedilol on Voltage-Dependent Na+ Channels in Cultured Bovine Adrenal Medullary Cells J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 212 - 218. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||